BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 9060552)

  • 1. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
    Brice P; Bastion Y; Lepage E; Brousse N; Haïoun C; Moreau P; Straetmans N; Tilly H; Tabah I; Solal-Céligny P
    J Clin Oncol; 1997 Mar; 15(3):1110-7. PubMed ID: 9060552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
    N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
    Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
    Cole BF; Solal-Céligny P; Gelber RD; Lepage E; Gisselbrecht C; Reyes F; Sebban C; Sugano D; Tendler C; Goldhirsch A
    J Clin Oncol; 1998 Jul; 16(7):2339-44. PubMed ID: 9667248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
    Bachy E; Brice P; Delarue R; Brousse N; Haioun C; Le Gouill S; Delmer A; Bordessoule D; Tilly H; Corront B; Allard C; Foussard C; Bosly A; Coiffier B; Gisselbrecht C; Solal-Celigny P; Salles G
    J Clin Oncol; 2010 Feb; 28(5):822-9. PubMed ID: 20026809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
    Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
    Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Wendum D; Sebban C; Gaulard P; Coiffier B; Tilly H; Cazals D; Boehn A; Casasnovas RO; Bouabdallah R; Jaubert J; Ferrant A; Diebold J; de Mascarel A; Gisselbrecht C
    J Clin Oncol; 1997 Apr; 15(4):1654-63. PubMed ID: 9193366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Céligny P; Brice P; Brousse N; Caspard H; Bastion Y; Haïoun C; Bosly A; Tilly H; Bordessoule D; Sebban C; Harousseau JL; Morel P; Dupas B; Plassart F; Vasile N; Fort N; Leporrier M
    J Clin Oncol; 1996 Feb; 14(2):514-9. PubMed ID: 8636765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
    Coiffier B; Neidhardt-Bérard EM; Tilly H; Belanger C; Bouabdallah R; Haioun C; Brice P; Péaud PY; Pico JL; Janvier M; Solal-Celigny P; Brousse N
    Ann Oncol; 1999 Oct; 10(10):1191-7. PubMed ID: 10586336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Sebban C; Mounier N; Brousse N; Belanger C; Brice P; Haioun C; Tilly H; Feugier P; Bouabdallah R; Doyen C; Salles G; Coiffier B
    Blood; 2006 Oct; 108(8):2540-4. PubMed ID: 16835383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.
    van der Kaaij MA; Heutte N; Le Stang N; Raemaekers JM; Simons AH; Carde P; Noordijk EM; Fermé C; Thomas J; Eghbali H; Kluin-Nelemans HC; Henry-Amar M; ;
    J Clin Oncol; 2007 Jul; 25(19):2825-32. PubMed ID: 17515571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
    Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
    Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
    J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Brugiatelli M; Luminari S; Lombardo M; Merli F; Sacchi S; Gobbi P; Liberati M; Cavanna L; Colombi M; Stelitano C; Goldaniga M; Morabito F; Federico M; Silingardi V;
    J Clin Oncol; 2003 Apr; 21(8):1459-65. PubMed ID: 12697867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.
    van der Kaaij MA; Heutte N; Meijnders P; Abeilard-Lemoisson E; Spina M; Moser EC; Allgeier A; Meulemans B; Simons AH; Lugtenburg PJ; Aleman BM; Noordijk EM; Fermé C; Thomas J; Stamatoullas A; Fruchart C; Brice P; Gaillard I; Bologna S; Ong F; Eghbali H; Doorduijn JK; Morschhauser F; Sebban C; Roesink JM; Bouteloup M; Van Hoof A; Raemaekers JM; Henry-Amar M; Kluin-Nelemans HC
    J Clin Oncol; 2012 Jan; 30(3):291-9. PubMed ID: 22184372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.